Love Pharma Inc (TSE:JOLT) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jolt Health Inc. has announced the acquisition of intellectual property for developing a transdermal patch technology for hydroxychloroquine (HCQ), aimed at improving treatments for malaria, lupus, and rheumatoid arthritis. The innovative delivery method is expected to mitigate side effects associated with oral HCQ and tap into a market projected to be worth $6 billion by 2027. This strategic move could revolutionize patient care in these underserved areas by utilizing a transdermal system that ensures safe and consistent drug dosage.
For further insights into TSE:JOLT stock, check out TipRanks’ Stock Analysis page.